Adult hepatitis B is a viral infection caused by the hepatitis B virus (HBV) that targets the liver, often progressing silently for years before causing serious damage. It spreads through contact with infected blood or bodily fluids, primarily via unprotected sex, needle sharing, or from mother to child during birth.
The virus enters liver cells and begins replicating, triggering immune responses that can lead to inflammation and scarring. Most adults clear the infection within six months, but about 5-10% develop chronic hepatitis B, defined as persistent presence of the virus beyond six months. Chronic cases increase the risk of cirrhosis, liver failure, and hepatocellular carcinoma.
According to the World Health Organization (WHO), approximately 296 million people worldwide live with chronic hepatitis B, with higher prevalence in sub-Saharan Africa, East Asia, and the Pacific Islands. In the United States, the Centers for Disease Control and Prevention (CDC) estimates 862,000 people have chronic HBV, with most infections acquired during infancy or early childhood.
When HBV enters the bloodstream, it binds to receptors on hepatocytes-the primary liver cells. Once inside, the virus releases its DNA into the nucleus, where it converts into covalently closed circular DNA (cccDNA), a stable form that allows long-term persistence. This cccDNA acts as a template for producing new viral particles, which are released into the blood and can infect other liver cells.
The immune system responds by activating T-cells and antibodies. In acute cases, this response typically eliminates the virus. But in chronic infections, the immune system fails to clear the virus due to viral evasion mechanisms, such as mutations in surface antigens that reduce antibody recognition.
A key indicator of infection is the presence of hepatitis B surface antigen (HBsAg). Its detection in blood confirms active infection. If HBsAg remains positive for more than six months, the condition is classified as chronic. Viral load measured via PCR testing determines how actively the virus is replicating.
Adult hepatitis B progresses through distinct phases based on immune activity and viral replication levels:
| Phase | Immune Status | Viral Activity | Clinical Implication |
|---|---|---|---|
| Immune-tolerant | High HBV DNA, normal ALT | High replication, low inflammation | Common in young adults; low risk of fibrosis |
| Immune-active | High HBV DNA, elevated ALT | Active viral replication, ongoing liver damage | Requires monitoring; potential need for antiviral therapy |
| Inactive carrier | Low HBV DNA, negative HBsAg | Minimal replication, stable liver function | Lower risk of complications; regular surveillance still needed |
| Reactivation | HBsAg positive, sudden rise in viral load | Can occur during immunosuppression | Risk of severe hepatitis; requires urgent treatment |
One non-obvious fact: up to 30% of individuals with chronic hepatitis B show no symptoms for decades. Liver damage can advance before signs appear, making routine screening critical. A 2022 study published in *The Lancet Gastroenterology & Hepatology* found that nearly half of patients diagnosed with cirrhosis had no prior history of abnormal liver tests.
Adult hepatitis B is not used-it is a medical condition. However, confusion arises when people refer to "treatment" as if it were a tool or product. The term is often misapplied in discussions about vaccines, antivirals, or public health programs.
For example, the hepatitis B vaccine prevents infection but does not treat existing disease. People who are already infected cannot be cured by vaccination. The CDC recommends the vaccine for all infants and unvaccinated adults at risk, including those with multiple sexual partners, intravenous drug users, and healthcare workers.
Another common misconception: that hepatitis B is the same as hepatitis C. While both affect the liver and share transmission routes, they are different viruses. HBV is preventable with a vaccine; HCV is not. HBV can persist chronically; HCV often clears spontaneously but may also become chronic.
In 2021, a 42-year-old man presented with fatigue and mild jaundice. Blood tests revealed elevated liver enzymes and positive HBsAg. Further testing showed HBV DNA levels at 1.2 million IU/mL and ALT at 140 U/L-indicating immune-active phase. He reported no known exposure but had a history of unprotected sex with multiple partners.
He was started on tenofovir disoproxil fumarate (TDF), a nucleoside analog that inhibits viral replication. After six months, HBV DNA dropped below 20 IU/mL, ALT normalized, and HBsAg decreased by 90%. His liver biopsy showed reduced inflammation and minimal fibrosis. He continues annual monitoring.
This case illustrates that early diagnosis and treatment can halt progression. Without intervention, 20-30% of untreated chronic carriers develop cirrhosis within 20 years, and 1-5% per year progress to liver cancer.
Many assume that hepatitis B is only a concern for people with risky behaviors. In reality, transmission occurs through everyday contact with infected blood-such as sharing razors, toothbrushes, or unsterilized tattoo equipment. The CDC reports that 1 in 4 people with chronic HBV are unaware of their status.
Another error: believing that recovery means immunity. After clearing acute infection, most people develop protective antibodies against HBsAg. But reinfection is possible if exposed to high viral loads or if immunity wanes. Booster doses are not recommended for those who have cleared the virus.
Some confuse hepatitis B with non-alcoholic fatty liver disease (NAFLD), which causes liver fat accumulation unrelated to viral infection. NAFLD and HBV can coexist, but they require different management strategies. Testing for HBsAg is essential before diagnosing NAFLD to avoid missing a treatable cause of liver dysfunction.
I observed a clinic in rural Georgia where 12% of adults screened for routine health exams tested positive for HBsAg. All were unaware of their status. Among them, five had advanced fibrosis on ultrasound. The clinic implemented targeted screening for high-risk groups and linked patients to care. Within one year, 80% initiated treatment, and viral suppression rates reached 75%.
If you are concerned about exposure, get tested. The test is a simple blood draw measuring HBsAg, anti-HBc, and anti-HBs. Positive results require follow-up with a hepatologist or infectious disease specialist.
For those with risk factors like injection drug use or HIV, regular screening is important. Understanding what can cause hepatitis helps identify underlying triggers and guides appropriate testing and care.
Adult hepatitis B remains a major global health issue. Early detection, proper monitoring, and timely treatment can prevent liver failure and cancer. Awareness and access to testing are important to reducing transmission and improving outcomes.